secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001213900-23-059044
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma executes 1-for-10 reverse stock split effective July 25, 2023 to regain Nasdaq compliance
--------------------------------------------------------------------------------

- 1-for-10 reverse stock split effective 12:01 a.m. EST July 25, 2023; new CUSIP 00091F 304.
- Pre-split outstanding shares 33,080,740; post-split approx 3,308,074 (no fractional shares, rounded up).
- Shareholder approval obtained at special meeting on July 7, 2023.
- Ticker symbol remains ABVC; split aims to increase per-share price to meet Nasdaq continued listing standards.
- Board expects reverse split to help exit penny-stock status and attract broader investor base.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023059044/0001213900-23-059044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023059044/ea182176-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-059044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer